Key Insights

Highlights

Treatment Research

2 treatments under study, led by Pascal Synthesis 577 Sham Topcon Corporation Tokyo Japan

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Not Applicable (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04847635Not ApplicableRecruiting

Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration

Showing all 1 trials

Research Network

Common Treatments

  • Pascal Synthesis 577 Sham Topcon Corporation Tokyo Japan1
  • Pascal Synthesis 577 Subthreshold Laser Topcon Corporation Tokyo Japan1

Active Sponsors

  • Fondazione G.B. Bietti, IRCCS1
  • Ospedale San Raffaele1
  • University of Genova1
  • University of Rome Tor Vergata1

Related Conditions

  • Laser Burn Of Retina1
  • Macular Degeneration Dry1
  • Macular Degeneration Senile1

Activity Timeline